JRCT ID: jRCT2032220496
Registered date:08/12/2022
PASSAGE Clinical Trial
Basic Information
Recruitment status | Recruiting |
---|---|
Health condition(s) or Problem(s) studied | Unresectable malignant gastric outlet obstruction |
Date of first enrollment | 23/12/2022 |
Target sample size | 51 |
Countries of recruitment | |
Study type | Interventional |
Intervention(s) | Investigational device (BSJ018A) will be implanted in the EUS-guided gastrojejunostomy |
Outcome(s)
Primary Outcome | GOOSS 3 rate without MAE at 30 days post procedure |
---|---|
Secondary Outcome |
Key inclusion & exclusion criteria
Age minimum | >= 18age old |
---|---|
Age maximum | Not applicable |
Gender | Both |
Include criteria | Unresectable malignant duodenal obstruction confirmed by biopsy Eligible for endoscopic intervention GOOSS score of 0 or 1 18 years of age or older Willing and able to comply with the study procedures or legally authorized representative (LAR) must provide written informed consent form (ICF) to participate in the study |
Exclude criteria | Exclusion Criteria at informed consent Prior metallic stent placement for GOO Contraindicated to surgery and general anesthesia Neoplasm invading the target site of puncture in gastric and/or jejunum Altered anatomy of the upper gastrointestinal tract due to surgery of esophagus, stomach and duodenum that might preclude endoscopic drainage Presence of ileus caused by peritoneal carcinomatosis, or expected to present within 30 days post procedure Intervening gastric varices or vessels at the target site of stent insertion Ascites that may interfere the safety of the index procedure Subject is currently participating, or plans to participate in, another investigational trial that may confound the results of this trial (unless written approval is received from the Boston Scientific study team) Vulnerable subject Exclusion Criteria at the index procedure Guidewire does not cross the area of GOO EP-DB does not advance to the target site in jejunum The distance between the gastric wall and jejunal wall when visualized on ultrasound after saline is introduced into the space between the two inflated balloons of EP-DB is deemed about 2 cm or more |
Related Information
Primary Sponsor | Kawahara Kazuo |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | |
Secondary ID(s) | NCT05644951 |
Contact
Public contact | |
Name | Ryo Konishi |
Address | 4-10-2 Nakano, Nakano-ku, Tokyo Tokyo Japan 164-0001 |
Telephone | +81-3-6853-7500 |
JapanClinicalTrials@bsci.com | |
Affiliation | Boston Scientific Japan K.K. |
Scientific contact | |
Name | Kazuo Kawahara |
Address | 4-10-2 Nakano, Nakano-ku, Tokyo Tokyo Japan 164-0001 |
Telephone | +81-3-6853-7500 |
JapanClinicalTrials@bsci.com | |
Affiliation | Boston Scientific Japan K.K. |